Skip to content
OpenCapital
Get started

Jazz Pharmaceuticals JAZZ Effect of cross-border tax laws

Effect of cross-border tax laws at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-0.1%—

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio2×-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercent.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's effect of cross-border tax laws.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's effect of cross-border tax laws?
Jazz Pharmaceuticals (JAZZ) reported effect of cross-border tax laws of -4.7% in Q4 2025.
What does effect of cross-border tax laws mean?
An additional adjustment reflecting the impact of international tax regulations.
How do you interpret effect of cross-border tax laws?
Provides granularity on how specific international tax regimes influence the effective tax rate.
How does effect of cross-border tax laws compare across companies?
Used by multinationals to reconcile complex global tax positions.